



OPEN ACCESS

EDITED AND REVIEWED BY
Zhiyong Guo,
Second Military Medical University,
China

*CORRESPONDENCE

Jin Shang,
fccshangj2@zzu.edu.cn
Zhanzheng Zhao,
zhanzhengzhao@zzu.edu.cn

SPECIALTY SECTION

This article was submitted to Renal
Pharmacology,
a section of the journal
Frontiers in Pharmacology

RECEIVED 19 October 2022
ACCEPTED 23 November 2022
PUBLISHED 22 December 2022

CITATION

Guo R, Wang P, Zheng X, Cui W, Shang J
and Zhao Z (2022), Corrigendum:
SGLT2 inhibitors suppress epithelial-
mesenchymal transition in podocytes
under diabetic conditions *via*
downregulating the IGF1R/
PI3K pathway.
Front. Pharmacol. 13:1074294.
doi: 10.3389/fphar.2022.1074294

COPYRIGHT

© 2022 Guo, Wang, Zheng, Cui, Shang
and Zhao. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions *via* downregulating the IGF1R/PI3K pathway

Ruixue Guo^{1,2}, Peipei Wang^{1,2}, Xuejun Zheng^{1,2}, Wen Cui^{1,2},
Jin Shang^{1,3,4*} and Zhanzheng Zhao^{1,3,4*}

¹Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, ²Zhengzhou University, Zhengzhou, China, ³Nephropathy Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, ⁴Laboratory Animal Platform of Academy of Medical Sciences, Zhengzhou, China

KEYWORDS

diabetic nephropathy, sodium-glucose cotransporter-2 inhibitors, insulin-like growth factor-1 receptor, podocyte, epithelial-mesenchymal transition


A Corrigendum on
[SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions *via* downregulating the IGF1R/PI3K pathway](#)


by Guo R, Wang P, Zheng X, Cui W, Shang J and Zhao Z (2022). *Front Pharmacol.* 13:897167.
doi: 10.3389/fphar.2022.897167


In the original article, there was a mistake in [Figure 1C](#), [Supplementary Figure S2](#), [Figure 3B](#), and [Figure 4](#) as published:

- (1) In Figure 1C and Supplementary Figure S2, the IHC images of IGF1R were erroneously used as the results of Collagen IV. The corrected IHC images of Collagen IV were displayed as below.
- (2) In Figure 3B, WB gels related to SGLT2 and IGF1R should be annotated according to Con-DA-DN. The corrected Figure 3B was displayed as below.
- (3) In Figure 4A, the annotation of WB gel for Nephryn and α -SMA was reversed. The corrected Figure 4A was displayed as below.
- (4) In Figures 4B,D, the annotation of the bar for Nephryn and α -SMA was reversed. The corrected Figure 4 was displayed as below.
- (5) Supplementary Figures S10–S12 are added as the raw data of Figures 3, 4 and Supplementary Figure S9.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.







Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.